AACR: New Drugs


At AACR, pharmaceutical and biotech companies are taking the opportunity to publicize some new and promising compounds they are testing to treat various kinds of cancer. AstraZeneca's Nigel Brooks presented AZD4547, a selective inhibitor of FGF receptors 1, 2, and 3. FGF and FGFR signaling occurs in many human tumors and controls tumor angiogenesis. According to Brooks, AZD4547 potently and selectively inhibits FGFR downstream signaling in cell lines. It has also been shown to cause dose-dependent tumor-growth inhibition in a Snu16 gastric xenograft model, he added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.